Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CARL JACK FICHTENBAUM

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1073578951
CMS profile
2920
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$28.43

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $28.43 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $28.43 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CARL JACK FICHTENBAUM

NPI 1073578951 · CMS profile ID 2920

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073578951?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CARL JACK FICHTENBAUM, NPI 1073578951, CMS profile ID 2920. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073578951?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CARL JACK FICHTENBAUM, NPI 1073578951, CMS profile ID 2920. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073578951?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CARL JACK FICHTENBAUM, NPI 1073578951, CMS profile ID 2920, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1073578951?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $28.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $28.4303/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695413811 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $28.43 1
PY2021 $99.00 1
PY2022 $6,617.41 7
PY2023 $2,560.30 16
PY2024 $249.93 3
PY2025 $2,462.10 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,213.04 4
PY2025 Principal investigator $578,272.21 59
PY2024 Recipient $473.50 2
PY2024 Principal investigator $223,284.75 51
PY2023 Recipient $1,149.35 11
PY2023 Principal investigator $65,128.22 19
PY2022 Principal investigator $109,613.44 27
PY2021 Recipient $12,898.30 1
PY2021 Principal investigator $167,018.23 49
PY2020 Principal investigator $181,285.60 70
PY2019 Principal investigator $263,157.10 91

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $1,579.10 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na HIV-1 Infected Subjects No dispute reported 06/30/2026 848741273
Principal investigator 1 Janssen Research & Development, LLC $930.00 12/27/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
Study to Evaluate Efficacy and Safety of Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Regimen Versus Boosted Protease Inhibitor bPI Along With Emtricitabine Tenofovir Disoproxil Fumarate FTCTDF Regimen in Virologically Suppressed HIV1 In No dispute reported 06/30/2026 787824019
Principal investigator 1 ViiV Healthcare Company $3,276.00 12/09/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 860857833
Principal investigator 1 ViiV Healthcare Company $1,000.00 12/02/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 860857537
Principal investigator 1 ViiV Healthcare Company $1,901.24 11/25/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIB, RANDOMIZED, PARTIALLY BLIND, ACTIVE CONTROLLED, DOSE-RANG No dispute reported 06/30/2026 803291801
Principal investigator 1 ViiV Healthcare Company $9,007.42 11/22/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 803291899
Principal investigator 1 ViiV Healthcare Company $2,600.00 11/03/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 860857523
Principal investigator 1 ViiV Healthcare Company $1,000.00 11/03/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 860857525
Principal investigator 1 ViiV Healthcare Company $390.00 11/03/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 860857533
Principal investigator 1 Amgen Inc. $1,995.00 10/23/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
Ph3b Evolocumab in HIV Patients No dispute reported 06/30/2026 830984613
Principal investigator 1 ViiV Healthcare Company $2,641.00 10/15/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 860857539
Principal investigator 1 ViiV Healthcare Company $235.98 10/15/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 860857545
Principal investigator 1 ViiV Healthcare Company $3,897.08 10/15/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 860857547
Principal investigator 1 Janssen Research & Development, LLC $930.00 08/30/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
Study to Evaluate Efficacy and Safety of Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Regimen Versus Boosted Protease Inhibitor bPI Along With Emtricitabine Tenofovir Disoproxil Fumarate FTCTDF Regimen in Virologically Suppressed HIV1 In No dispute reported 06/30/2026 787824003
Principal investigator 1 ViiV Healthcare Company $4,289.83 08/20/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIB, RANDOMIZED, PARTIALLY BLIND, ACTIVE CONTROLLED, DOSE-RANG No dispute reported 06/30/2026 803290723
Principal investigator 1 ViiV Healthcare Company $3,252.60 08/19/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 803290611
Principal investigator 1 ViiV Healthcare Company $8,327.02 07/29/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIB, RANDOMIZED, PARTIALLY BLIND, ACTIVE CONTROLLED, DOSE-RANG No dispute reported 06/30/2026 803290529
Principal investigator 1 ViiV Healthcare Company $10,658.74 07/20/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 803290401
Principal investigator 1 ViiV Healthcare Company $600.00 07/20/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO No dispute reported 06/30/2026 803291219
Principal investigator 1 ViiV Healthcare Company $150.00 07/15/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 860857535
Principal investigator 1 ViiV Healthcare Company $2,862.03 07/07/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIB, RANDOMIZED, PARTIALLY BLIND, ACTIVE CONTROLLED, DOSE-RANG No dispute reported 06/30/2026 803290527
Principal investigator 1 Gilead Sciences, Inc. $726.00 06/23/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 803516315
Principal investigator 1 Gilead Sciences, Inc. $1,719.00 06/23/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 803516317
Principal investigator 1 ViiV Healthcare Company $7,700.00 06/07/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIB, RANDOMIZED, PARTIALLY BLIND, ACTIVE CONTROLLED, DOSE-RANG No dispute reported 06/30/2026 803290513
Principal investigator 1 ViiV Healthcare Company $2,500.00 06/07/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIB, RANDOMIZED, PARTIALLY BLIND, ACTIVE CONTROLLED, DOSE-RANG No dispute reported 06/30/2026 803290515
Principal investigator 1 ViiV Healthcare Company $2,500.00 06/07/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIB, RANDOMIZED, PARTIALLY BLIND, ACTIVE CONTROLLED, DOSE-RANG No dispute reported 06/30/2026 803290517
Principal investigator 1 ViiV Healthcare Company $2,700.00 06/07/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIB, RANDOMIZED, PARTIALLY BLIND, ACTIVE CONTROLLED, DOSE-RANG No dispute reported 06/30/2026 803290519
Principal investigator 1 ViiV Healthcare Company $2,700.00 06/07/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIB, RANDOMIZED, PARTIALLY BLIND, ACTIVE CONTROLLED, DOSE-RANG No dispute reported 06/30/2026 803290521
Principal investigator 1 Janssen Research & Development, LLC $17,027.00 05/31/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
Study to Evaluate Efficacy and Safety of Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Regimen Versus Boosted Protease Inhibitor bPI Along With Emtricitabine Tenofovir Disoproxil Fumarate FTCTDF Regimen in Virologically Suppressed HIV1 In No dispute reported 06/30/2026 787823989
Principal investigator 1 Gilead Sciences, Inc. $1,119.00 05/19/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 803516311
Principal investigator 1 Gilead Sciences, Inc. $1,719.00 05/19/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 803516313
Principal investigator 1 ViiV Healthcare Company $2,445.30 05/12/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 803289875
Principal investigator 1 Gilead Sciences, Inc. $791.00 04/26/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 803516307
Principal investigator 1 Gilead Sciences, Inc. $809.00 04/26/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 803516309
Principal investigator 1 ViiV Healthcare Company $10,072.46 04/12/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 803289479
Principal investigator 1 ViiV Healthcare Company $800.80 04/08/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO No dispute reported 06/30/2026 803291221
Principal investigator 1 Gilead Sciences, Inc. $3,950.00 03/17/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 803516305
Principal investigator 1 Gilead Sciences, Inc. $1,425.00 03/08/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumaratein HIV and HBV Treatment Naive in Hepatitis B and HIV-1 Co-Infected Adults No dispute reported 06/30/2026 803516303
Principal investigator 1 Janssen Research & Development, LLC $1,320.00 03/08/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
Study to Evaluate Efficacy and Safety of Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Regimen Versus Boosted Protease Inhibitor bPI Along With Emtricitabine Tenofovir Disoproxil Fumarate FTCTDF Regimen in Virologically Suppressed HIV1 In No dispute reported 06/30/2026 787823957
Principal investigator 1 Janssen Research & Development, LLC $15,840.00 03/08/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
Study to Evaluate Efficacy and Safety of Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Regimen Versus Boosted Protease Inhibitor bPI Along With Emtricitabine Tenofovir Disoproxil Fumarate FTCTDF Regimen in Virologically Suppressed HIV1 In No dispute reported 06/30/2026 787823971
Principal investigator 1 ViiV Healthcare Company $2,553.60 02/27/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 803291437
Principal investigator 1 Gilead Sciences, Inc. $791.00 02/17/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 803516299
Principal investigator 1 Gilead Sciences, Inc. $809.00 02/17/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 803516301
Principal investigator 1 ViiV Healthcare Company $1,638.00 02/11/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 803288881
Principal investigator 1 Eli Lilly and Company $10,072.80 01/26/2021 Non-covered Recipient Entity
ELI LILLY
A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENTING SARS COV 2 INFECTION AND COVID 19 IN SKILLED NURSING AND ASSISTED LIVING FACILITY RESIDENTS AND STAFF A NIAID AND LILLY COLLABORATIVE STUDY No dispute reported 06/30/2026 819456761
Principal investigator 1 ViiV Healthcare Company $8,927.23 01/14/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 803288959
Principal investigator 1 ViiV Healthcare Company $300.00 01/12/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 803288911
Principal investigator 1 ViiV Healthcare Company $300.00 01/12/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 803289043
Recipient Eli Lilly and Company $12,898.30 01/11/2021 Covered Recipient Physician A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENTING SARS COV 2 INFECTION AND COVID 19 IN SKILLED NURSING AND ASSISTED LIVING FACILITY RESIDENTS AND STAFF A NIAID AND LILLY COLLABORATIVE STUDY No dispute reported 06/30/2026 819443501
Principal investigator 1 Gilead Sciences, Inc. $2,240.00 01/06/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 803516297